Scientists from Weill Cornell Medicine have created a small module of cell lung cancer that helps them to understand how the disease is started and how it is; going on.
News David Litman
The model has already enabled Joyce Chen, the managing author and colleagues, to make an important search of two tumor tumors that are often matched in this highly aggressive and fatal way of lung cancer.
Smokers in a small lung cancer are just a disease. In general, it will be resistant to remedies such as chemotherapy within a few months. Despite attempts to improve new healing, little progress has been made and ultimately, the US Congress and the National Institute have visited; The disease determines the "suffering" cancer.
Cancer is thought to have a & # 39; comes from a specific division of lung cells called neuroendocrine cells (pNEC). However, researchers do not know how to make different human creatures cells into PNECs.
Now, Chen says: "We found a way to stimulate neuroendocrine cells such as cultural human cell cells after the initial difference into the lung cells. We did this by making & # 39; important path barrier of cell markers called NECH path. "
Almost all patients with small lung cancer cells deteriorate in the tumor suppressor genera RB and TP53South-West Chen and colleagues have now discovered that advanced cotton cells can create more PNECs when they are RB Gene to prevent it and that those PNECs have to do so; shows a set of gene that is closely related to the one seen in the early SCLC tunnels.
The next thing, researchers have hindered them TP53, leading to PNECs to start & # 39; shows a generation that promotes cell growth and death death. Following the PNEC culture, the team gave them a mice.
As mentioned in Journal of Experimental MedicineFind Chen and colleagues that PNECS slowly started tumors in the animals, suggest that it is a method in RB and TP53 which affects the start of disease.
"Our system should further investigate the progress of these early stage tumors into aggressive SCLCs similar to the more aggressive cans in patients," said co-director Harold Varmus. "If so, it should be possible to determine cells at different levels of tumor development for susceptibility and to tackle medication strategies."